英文摘要 |
Patients with advanced non-small cell lung cancer need long-term treatment for targeted therapy. About 90–100% of the patients receiving EGFR-tyrosine kinase inhibitor will experience skin toxicities after one week of targeted therapy. Patients also experience other side effects sequentially half a year after treatment. These skin reactions are inevitable but controllable. Therefore, providing effective education in appropriate time is critical. The purpose of this study was to explore several common skin toxicities among patients receiving targeted therapy for less than and more than one month and compare the difference in severity. This study is an exploratory and cross-sectional design. Convenient sampling was used to recruit patients from thoracic and oncology ward and outpatient department of a medical center in northern Taiwan. One hundred and forty-nine patients were included in this study from July 2015 to March 2016. Results showed that more than 50% patients both receiving targeted therapy for less than and more than one month have experiences of dry skin, pruritus, rash acneiform, and/or oral mucositis. Half of the patients experienced paronychia within 1 to 3 months after treatment. There is a significant difference in the incidence of paronychia between patients receiving treatment for less than and more than one month (χ2 =4.478, p< .05). Health care provider need to provide a comprehensive education of skin and oral care to the patients in the initial stage of targeted therapy. Finger and toe care are especially emphasized one month after treatment. By emphasizing timely care to patients and their family members, this study promotes the value of education and patient’s skin care ability and quality of life. |